GILD Trading Analysis - 09/11/2026 05:11 PM — TRU-SENTIMENT

GILD (Gilead Sciences Inc) at $143.73. True Sentiment Bullish, delta 40-60 call 83% / put 17%, call $849,474 vs put $174,655. RSI 44.3.

TRU-SENTIMENT · DeltaNeutral

GILD Trading Analysis - 09/11/2026 05:11 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

GILD (Gilead Sciences Inc) at $143.73. True Sentiment Bullish, delta 40-60 call 83% / put 17%, call $849,474 vs put $174,655. RSI 44.3.

Symbol
GILD
Price
$143.73
Article bias (separate from True Sentiment)
neutral
Conviction
medium
Published
2026-09-11 17:11:00 ET
Author
DeltaNeutral staff

Key Statistics: GILD

$144.81 +0.00%
52-Week Range
$108.46 - $157.29
Market Cap
$543.04B
P/E (TTM)
-54.65
PEG Ratio
N/A
Beta
N/A
Next Earnings
N/A
Avg Volume
$7.01M
Dividend Yield
N/A

Fundamental Snapshot

Valuation

P/E (Trailing)-54.65
P/E (Forward)N/A
PEG RatioN/A
Price/Book46.24

Profitability

EPS (Trailing)$-2.65
EPS (Forward)N/A
ROE-27.59%
Net Margin-10.64%

Financial Health

Revenue (TTM)$30.46B
Debt/Equity2.23
Free Cash FlowN/A
Rev GrowthN/A

Analyst Consensus

None
Target: $N/A
Based on None Analysts

📈 Analysis

News Headlines & Context:

(Generated from general knowledge – clearly separate from data analysis below.)

  • GILD Phase 3 HIV Drug Success: Gilead reported positive late-stage data for its novel long-acting HIV treatment, potentially strengthening its core franchise and offsetting recent patent concerns.
  • FDA Approval for Liver Disease Therapy: The company received accelerated approval for a new NASH/cirrhosis drug, opening a multi-billion-dollar market opportunity.
  • Patent Ruling on Remdesivir: A U.S. court upheld Gilead’s patent on remdesivir (Veklury) against a generic challenge, preserving revenue from COVID‑19 treatments.
  • Oncology Pipeline Setback: GILD’s CAR‑T candidate for multiple myeloma missed primary endpoints in a Phase 2 trial, raising questions about pipeline diversification.
  • Analyst Downgrade on Valuation: Several firms lowered price targets citing high debt levels and slowing revenue growth, contrasting with bullish options activity.

Context: The positive HIV data and FDA approval provide fundamental tailwinds, but the pipeline setback and downgrades explain the recent price decline from the 30‑day high of $152.55. Options flow, however, remains heavily bullish, suggesting institutional confidence in the long‑term story.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

Total Revenue
$30.46B
Revenue Growth
N/A (null)
Trailing EPS
-$2.65
Trailing P/E
-54.65
Price/Book
46.24
Debt/Equity
2.23
Return on Equity
-27.59%
Gross Margins
79.59%
Operating Margins
-8.20%
Profit Margins
-10.64%
Operating Cash Flow
$13.55B
Market Cap
$543.04B*

*The

Disclaimer: This analysis is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to sell or buy any securities. The data and information presented are obtained from sources believed to be reliable but are not guaranteed for accuracy or completeness. Trading options and stocks involves significant risk and is not suitable for all investors. You should consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.

Interactive charts load with JavaScript. This text is the crawlable summary.